Back to results
US 10,300,140 B2Granted
Sur-binding proteins against ERBB3
AssigneeI2 Pharmaceuticals, Inc.
InventorsRamesh R. Bhatt, Pamela K. Foreman, Lawrence C. Horowitz, Michael Horowitz, Medini Gore, Phil Kobel
Life of this patent
Estimating the term…
Abstract
Embodiments concern constructs comprising surrogate light chain sequences. In particular, embodiments concern constructs that can bind to ErbB3 and aspects relating to such constructs.
Claims7
A sur-binding protein comprising:
- (i) a surrogate light chain (SLC) sequence comprising, from N-terminus to C-terminus, a VpreB1 sequence covalently fused to a λ5 sequence, wherein the SLC sequence comprises the amino acid sequence of SEQ ID NO:
- 276;
- and
- (ii) a heavy chain variable region amino acid sequence comprising:
- (a) a heavy chain complementarity determining region (CDR) 1 sequence comprising SEQ ID NO:
- 39, a heavy chain CDR2 sequence comprising SEQ ID NO:
- 40, and a heavy chain CDR3 sequence comprising SEQ ID NO:
- 41;
- or
- (b) a heavy chain CDR1 sequence comprising SEQ ID NO:
- 43, a heavy chain CDR2 sequence comprising SEQ ID NO:
- 44, and a heavy chain CDR3 sequence comprising SEQ ID NO:
- 45;
- wherein the heavy chain variable region amino acid sequence is conjugated to the SLC sequence to form a sur-binding protein, and wherein said sur-binding protein specifically binds to an ErbB3 protein.
11 more elements
A bispecific sur-binding protein comprising:
- (i) a first surrogate light chain (SLC) sequence comprising, from N-terminus to C-terminus, a VpreB1 sequence covalently fused to a λ5 sequence, wherein the first SLC sequence comprises the amino acid sequence of SEQ ID NO:
- 276;
- (ii) a first heavy chain variable region amino acid sequence comprising:
- (a) a heavy chain complementarity determining region (CDR) 1 sequence comprising SEQ ID NO:
- 39, a heavy chain CDR2 sequence comprising SEQ ID NO:
- 40, and a heavy chain CDR3 sequence comprising SEQ ID NO:
- 41;
- or
- (b) a heavy chain CDR1 sequence comprising SEQ ID NO:
- 43, a heavy chain CDR2 sequence comprising SEQ ID NO:
- 44, and a heavy chain CDR3 sequence comprising SEQ ID NO:
- 45,
- wherein the first heavy chain variable region amino acid sequence is paired with the first SLC sequence to form a first sur-binding protein binding site, wherein the first sur-binding protein binding site binds to an ErbB3 protein;
- and
- (iii) a second SLC sequence comprising, from N-terminus to C-terminus, a VpreB1 sequence covalently fused to a λ5 sequence, wherein the second SLC sequence comprises the amino acid sequence of SEQ ID NO:
- 276;
- and
- (iv) a second heavy chain variable region amino acid sequence that is paired with the second SLC sequence to form a second sur-binding protein site, wherein the second sur-binding protein site binds to a second target.
15 more elements
A method for suppressing tumor growth in a subject comprising providing an ErbB3 sur-binding protein to a tumor in the subject, wherein the tumor comprises a cell that expresses ErbB3, thereby suppressing tumor growth, wherein the ErbB3 sur-binding protein comprises:
- (i) a surrogate light chain (SLC) sequence comprising, from N-terminus to C-terminus, a VpreB1 sequence covalently fused to a λ5 sequence, wherein the SLC sequence comprises the amino acid sequence of SEQ ID NO:
- 276;
- and
- (ii) a heavy chain variable region amino acid sequence comprising:
- (a) a heavy chain complementarity determining region (CDR) 1 sequence comprising SEQ ID NO:
- 39, a heavy chain CDR2 sequence comprising SEQ ID NO:
- 40, and a heavy chain CDR3 sequence comprising SEQ ID NO:
- 41;
- or
- (b) a heavy chain CDR1 sequence comprising SEQ ID NO:
- 43, a heavy chain CDR2 sequence comprising SEQ ID NO:
- 44, and a heavy chain CDR3 sequence comprising SEQ ID NO:
- 45;
- wherein the heavy chain variable region amino acid sequence is conjugated to the SLC sequence to form the ErbB3 sur-binding protein.
11 more elements
Dependencies are inferred from the claim text.